Results for "European Society of Cardiology"

The pharmaceutical company showcased long-term efficacy and safety results for mavacamten in treating obstructive hypertrophic cardiomyopathy at a major cardiology conference.

CRISPR Therapeutics has presented initial clinical trial results for CTX310, a gene-editing treatment aimed at lowering triglycerides and LDL cholesterol, showing durable genetic modifications at the European Society of Cardiology congress.

Alnylam Pharmaceuticals is scheduled to present new clinical data on its ATTR and hypertension drugs at the upcoming European Society of Cardiology (ESC) conference.

Professor Konstantinos Toutouzas, president of the Hellenic Cardiological Society, has been elected to the Board of Directors of the European Society of Cardiology (ESC) for the 2026–2028 term, strengthening Greece's presence.

Cytokinetics announced additional clinical trial results for its ACACIA-HCM and MAPLE-HCM programs during a late-breaking session at the European Society of Cardiology Congress, advancing treatments for hypertrophic cardiomyopathy.

Cytokinetics has released comprehensive results from its late-stage clinical trial demonstrating significant efficacy for a novel therapy treating non-obstructive hypertrophic cardiomyopathy. The findings were presented at the European Society of Cardiology congress and published in a leading medical journal.

New analyses from the REDUCE-IT® trial and EPA mechanistic data are scheduled for presentation at the European Society of Cardiology (ESC) Congress in 2026.

Leading European cardiologists have released new dietary recommendations for heart patients, emphasizing the importance of home cooking and avoiding processed foods.

Tenax Therapeutics announced it will showcase late-breaking scientific data from its Phase 3 LEVEL clinical trial during upcoming sessions at the European Society of Cardiology Congress.

New data presented at the European Society of Cardiology Congress 2026 indicates that adherent patients continue to experience cardiovascular benefits even after stopping Icosapent Ethyl treatment. The legacy analysis underscores the long-term impact of the therapy on heart health outcomes.

Greece strengthens its presence in the European scientific community as Professor Konstantinos Toufoutzas, president of the Hellenic Cardiological Society, was elected to the Board of the European Society of Cardiology (ESC).

Barbara Casadei, a cardiologist, has made history as the first woman to lead the European Society of Cardiology and the first non-American editor-in-chief of the JAMA journal group, challenging gender norms in the medical field.